These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
289 related items for PubMed ID: 27356689
1. Diagnostic Performance of Whole-Body Diffusion-Weighted Imaging Compared to PET-CT Plus Brain MRI in Staging Clinically Resectable Lung Cancer. Usuda K, Sagawa M, Maeda S, Motono N, Tanaka M, Machida Y, Matoba TM, Watanabe N, Tonami H, Ueda Y, Uramoto H. Asian Pac J Cancer Prev; 2016; 17(6):2775-80. PubMed ID: 27356689 [Abstract] [Full Text] [Related]
4. Staging performance of whole-body DWI, PET/CT and PET/MRI in invasive ductal carcinoma of the breast. Catalano OA, Daye D, Signore A, Iannace C, Vangel M, Luongo A, Catalano M, Filomena M, Mansi L, Soricelli A, Salvatore M, Fuin N, Catana C, Mahmood U, Rosen BR. Int J Oncol; 2017 Jul; 51(1):281-288. PubMed ID: 28535000 [Abstract] [Full Text] [Related]
11. Comparison between whole-body MRI with diffusion-weighted imaging and PET/CT in staging newly diagnosed FDG-avid lymphomas. Albano D, Patti C, La Grutta L, Agnello F, Grassedonio E, Mulè A, Cannizzaro G, Ficola U, Lagalla R, Midiri M, Galia M. Eur J Radiol; 2016 Feb; 85(2):313-8. PubMed ID: 26781135 [Abstract] [Full Text] [Related]
12. Multiparametric whole-body 3.0-T MRI in newly diagnosed intermediate- and high-risk prostate cancer: diagnostic accuracy and interobserver agreement for nodal and metastatic staging. Johnston EW, Latifoltojar A, Sidhu HS, Ramachandran N, Sokolska M, Bainbridge A, Moore C, Ahmed HU, Punwani S. Eur Radiol; 2019 Jun; 29(6):3159-3169. PubMed ID: 30519933 [Abstract] [Full Text] [Related]
13. [Whole-body staging of malignant melanoma: advantages, limitations and current importance of PET-CT, whole-body MRI and PET-MRI]. Pfannenberg C, Schwenzer N. Radiologe; 2015 Feb; 55(2):120-6. PubMed ID: 25589421 [Abstract] [Full Text] [Related]
14. Diffusion-weighted MR imaging in comparison to integrated [¹⁸F]-FDG PET/CT for N-staging in patients with lung cancer. Pauls S, Schmidt SA, Juchems MS, Klass O, Luster M, Reske SN, Brambs HJ, Feuerlein S. Eur J Radiol; 2012 Jan; 81(1):178-82. PubMed ID: 20932700 [Abstract] [Full Text] [Related]
15. Diagnostic value of whole body diffusion-weighted MRI compared to computed tomography for pre-operative assessment of patients suspected for ovarian cancer. Michielsen K, Dresen R, Vanslembrouck R, De Keyzer F, Amant F, Mussen E, Leunen K, Berteloot P, Moerman P, Vergote I, Vandecaveye V. Eur J Cancer; 2017 Sep; 83():88-98. PubMed ID: 28734146 [Abstract] [Full Text] [Related]
16. Prospective comparison of 18-FDG PET/CT and whole-body diffusion-weighted MRI in the assessment of multiple myeloma. Mesguich C, Hulin C, Latrabe V, Lascaux A, Bordenave L, Hindié E, Marit G. Ann Hematol; 2020 Dec; 99(12):2869-2880. PubMed ID: 32951093 [Abstract] [Full Text] [Related]
17. Whole-body MRI, including diffusion-weighted imaging, for the initial staging of malignant lymphoma: comparison to computed tomography. Kwee TC, van Ufford HM, Beek FJ, Takahara T, Uiterwaal CS, Bierings MB, Ludwig I, Fijnheer R, Nievelstein RA. Invest Radiol; 2009 Oct; 44(10):683-90. PubMed ID: 19724232 [Abstract] [Full Text] [Related]
20. Diagnostic value of whole-body diffusion-weighted magnetic resonance imaging for detection of primary and metastatic malignancies: a meta-analysis. Li B, Li Q, Nie W, Liu S. Eur J Radiol; 2014 Feb; 83(2):338-44. PubMed ID: 24355655 [Abstract] [Full Text] [Related] Page: [Next] [New Search]